Primary Radiation Therapy in Patients With Localized Orbital Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)

Journal Article · Sat May 01 04:00:00 EDT 2010 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2009.04.018· OSTI ID:21372244

Son, Seok Hyun; Choi, Byung Ock; Kim, Gi Won ^[1]; Yang, Suk Woo ^[2]; Hong, Young Seon ^[3]; Choi, Ihl Bohng ^[4]

---

1. Department of Radiation Oncology, College of Medicine, Catholic University of Korea, Seoul (Korea, Republic of)
2. Department of Ophthalmology, College of Medicine, Catholic University of Korea, Seoul (Korea, Republic of)
3. Department of Hemato-Oncology, College of Medicine, Catholic University of Korea, Seoul (Korea, Republic of)
4. Cyberknife Center of Gimpo Wooridul Spine Hospital, Seoul (Korea, Republic of)

Purpose: To evaluate the outcomes of patients with localized orbital marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) who were treated with radiotherapy (RT). Methods and Materials: We retrospectively reviewed the records of 46 patients who were treated with RT for pathologically confirmed localized stage IE marginal zone B-cell lymphoma of MALT. The radiation dose ranged from 21.6 to 45 Gy (median, 30.6 Gy) at 1.8-2.0 Gy per fraction. Median follow-up duration was 32.3 months (range, 3.1-113.6 months). Results: Forty-three patients (93%) achieved complete remission (CR), and three patients (7%) achieved partial remission (PR). Five-year relapse-free survival, cause-specific survival, and overall survival were 93%, 100%, and 100%, respectively. Among the patients with CR, two had recurrence at three sites. One patient relapsed locally and was successfully salvaged with reirradiation. The other patient relapsed in a distant site and was successfully treated with six cycles of CHOP chemotherapy. Late complications were noted in four patients. Two patients developed cataracts at 26 and 37 months after completion of RT. The other two patients developed nasolacrimal duct obstructions at 4 and 11 months after completion of RT. Conclusion: Our study showed that a modest dose of RT is an excellent treatment modality with low complication and recurrence rates. We suggest that a dose of 30.6 Gy is tolerable and sufficient for treating orbital MALT lymphoma. Even following recurrence, successful salvage is possible with RT or chemotherapy.

• OSTI ID: 21372244
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 1 Vol. 77; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
DISEASES
DOSES
IMMUNE SYSTEM DISEASES
LYMPHOMAS
MEDICINE
MEMBRANES
MUCOUS MEMBRANES
NEOPLASMS
NUCLEAR MEDICINE
RADIATION DOSES
RADIOLOGY
RADIOTHERAPY
THERAPY